Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Eagle Pharmaceuticals Reports Third Quarter 2019 Results
November 12, 2019 6:51 AM EST-- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 --
-- Plan to initiate a clinical trial in December for Eagles innovative fulvestrant program, which has the potential to result in greater inhibition of estrogen receptors and better outcomes for patients with estrogen receptor-positive breast cancer --
-- Company returned to 2019 Hajj and enrolled additional EHS patients in its controlled clinical study --
-- Eagle expects to file a... More
